Health Care & Hospital Law
Oct. 8, 2011
Pharmaceutical companies struggle to stay ahead of patent cliff
Biotechnology and pharmaceutical companies are executing plans to keep sales revenue from falling over the industry's so-called "patent cliff" as more than $100 billion worth of drugs lose patent protection over the next five years.
Daily Journal Staff Writer
Biotechnology and pharmaceutical companies are executing plans to keep sales revenue from falling over the industry's so-called "patent cliff" as more than $100 billion worth of drugs lose patent protection over the next five years.
Many drugmakers with top-selling products develop strategies early on that layer new patents on top of old ones to protect brand-name medicines, according t...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In